The effect of statins on sympathetic activity: a meta-analysis

Clinical Autonomic Research

Volumn 25, Issue 2, 2015, Pages 125-131

  Lewandowski, Jacek ^a   Symonides, Bartosz ^a   Gaciong, Zbigniew ^a   Siński, Maciej ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Microneurography; Statin; Sympathetic nervous activity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADRENERGIC SYSTEM; DRUG EFFECTS; HEART RATE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 84939965323     PISSN: 09599851     EISSN: 16191560     Source Type: Journal    
DOI: 10.1007/s10286-015-0274-1     Document Type: Article

References (30)

1. Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96(5A):24F–33F. doi:10.1016/j.amjcard.2005.06.009
2. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118. doi:10.1146/annurev.pharmtox.45.120403.095748
3. Millar PJ, Floras JS (2014) Statins and the autonomic nervous system. Clin Sci Lond 126(6):401–415. doi:10.1042/CS20130332
4. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG (2001) Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 157(2):463–469. doi:10.1016/S0021-9150(00)00746-2
5. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B (2005) Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11(9):684–690. doi:10.1016/j.cardfail.2005.06.439
6. Riahi S, Christensen JH, Toft E, Skou HA, Schmidt EB (2002) HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 45(6):479–483. doi:10.1006/phrs.2002.0988
7. Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP, Niebuhr U, Christensen JH, Toft E (2006) The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. Int J Cardiol 111(3):436–441. doi:10.1016/j.ijcard.2005.08.032
8. Gentlesk PJ, Wiley T, Taylor AJ (2005) A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 150(3):478–483. doi:10.1016/j.ahj.2004.10.031
9. Melenovsky V, Wichterle D, Simek J, Malik J, Haas T, Ceska R, Malik M (2003) Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. Am J Cardiol 92(3):337–341. doi:10.1016/S0002-9149(03)00643-X
10. Moreira ED, Mostarda CT, Moraes-Silva IC, Ferreira JB, Dos Santos F, Lacchini S, De Angelis K, Rodrigues B, Irigoyen MC (2013) Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors. Physiol Rep 1(3):e00045. doi:10.1002/phy2.45
11. Horwich TB, Middlekauff HR, Maclellan WR, Fonarow GC (2011) Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail 17(11):879–886. doi:10.1016/j.cardfail.2011.07.008
12. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW (2010) Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 74(12):2622–2626. doi:10.1253/circj.CJ-10-0427
13. Lewandowski J, Sinski M, Bidiuk J, Abramczyk P, Dobosiewicz A, Ciarka A, Gaciong Z (2010) Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res 33(10):1038–1043. doi:10.1038/hr.2010.137
14. McGowan CL, Murai H, Millar PJ, Notarius CF, Morris BL, Floras JS (2013) Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart 99(4):240–246. doi:10.1136/heartjnl-2012-302980
15. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, Zucker IH, Fadel PJ (2012) Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 303(3):H377–H385. doi:10.1152/ajpheart.00289.2012
16. Siddiqi L, Joles JA, Oey PL, Blankestijn PJ (2011) Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens 29(11):2176–2180. doi:10.1097/HJH.0b013e32834ae3c7
17. Sinski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, Gaciong Z (2009) Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 67(6):613–620
18. Gomes ME, Lenders JW, Bellersen L, Verheugt FW, Smits P, Tack CJ (2010) Sympathoinhibitory effect of statins in chronic heart failure. Clin Auton Res 20(2):73–78. doi:10.1007/s10286-009-0041-2
19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. doi:10.1371/journal.pmed.1000097
20. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81(5):582–587. doi:10.1016/S0002-9149(97)00965-X
21. Grassi G, Esler M (1999) How to assess sympathetic activity in humans. J Hypertens 17(6):719–734
22. Kishi T, Hirooka Y (2010) Sympathoinhibitory effects of atorvastatin in hypertension. Circ J 74(12):2552–2553. doi:10.1253/circj.CJ-10-1024
23. Lewandowski J, Sinski M, Puchalska L, Symonides B, Gaciong Z (2014) Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. J Am Soc Hypertens 8(10):715–723. doi:10.1016/j.jash.2014.06.003
24. Briasoulis A, Agarwal V, Valachis A, Messerli FH (2013) Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich) 15(5):310–320. doi:10.1111/jch.12081
25. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, Narkiewicz K, Rysz J, Ray KK, Abdollahi M, Lipid Blood Pressure, Meta-Analysis Collaboration G (2013) The effects of statins on blood pressure in normotensive or hypertensive subjects—a meta-analysis of randomized controlled trials. Int J Cardiol 168(3):2816–2824. doi:10.1016/j.ijcard.2013.03.068
26. Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, Oleszczak B, Sinski M, Firczuk M, Bujnicki JM, Chlebowska J, Staruch AD, Glodkowska-Mrowka E, Kunikowska J, Krolicki L, Szablewski L, Gaciong Z, Koziak K, Jakobisiak M, Golab J, Nowis DA (2012) Statins impair glucose uptake in tumor cells. Neoplasia 14(4):311–323
27. Kontopantelis E, Springate DA, Reeves D (2013) A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One 8(7):e69930. doi:10.1371/journal.pone.0069930
28. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48
29. Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi P, Riccardi G, Storey R, Wood D (2013) 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens 31(10):1925–1938. doi:10.1097/HJH.0b013e328364ca4c
30. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, Catapano AL, Reiner Z, Luscher TF (2014) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35(15):960–968. doi:10.1093/eurheartj/ehu107